Dose-dependent effects, safety and tolerability of fenugreek in diet-induced metabolic disorders in rats

Etsuko Muraki1*, Yukie Hayashi2, Hiroshige Chiba1, Nobuyo Tsunoda1 and Keizo Kasono1

Abstract

Background: We previously reported that fenugreek (Trigonella foenum-graecum L.) improved diet-induced metabolic disorders in rats. The purpose of the present study was to examine the dose-dependent effects, safety and tolerability of fenugreek.

Methods: The diets used in this study were the high-fat high-sucrose diet (HFS; lard 50% kcal, sucrose 25% kcal) as a control (Ctrl group) or the HFS containing 0.25% (VL group), 1.25% (L group), 2.50% (M group), 5.00% (H group) or 12.30% (VH group) fenugreek based on the modified version of the AIN-93G purified diet.

Results: Fenugreek dose-dependently reduced the hepatic triglyceride and total cholesterol levels. Fenugreek also dose-dependently increased the excretion of cholesterol and total bile acids into the feces. However, the glucose tolerance showed no significant change by fenugreek administration. The VL and L groups did not significantly change triglyceride or total cholesterol levels in the liver. The VL group showed no increase in excretion of triglyceride, total cholesterol or bile acids in the feces. The VH group showed appetite reduction and diarrhea, while no adverse effect or symptoms were observed in the M group.

Conclusion: These results suggest that fenugreek inhibited lipid accumulation in the liver by increasing the lipid excretion in the feces. The effective, safe and tolerable dose of fenugreek was found to be around 2.50% (w/w).

Keywords: fenugreek, high-fat high-sucrose diet, diet-induced metabolic disorders, rats

Background

Recently, the incidence of lifestyle-related diseases including metabolic disorders has been expanding in parallel with rapid economic development in advanced countries. The principle therapeutic policy for these diseases lies in the improvement of dietary habits and the increase of physical activity. However, it is difficult to control and modify one’s usual lifestyle. In that case, functional foods with preventive and therapeutic effects on metabolic disorders are very helpful for the improvement of lifestyle-related diseases. On the other hand, the excessive intake of some functional foods may result in adverse effects. However, a lot of such functional foods are actually available at the market, though their safety has not been confirmed [1].

It has been reported that the active components of fenugreek, 4-hydroxyisoleucine and galactomannan, lowered blood glucose levels and improved lipid metabolism in vivo [2-5]. Fenugreek also contains dioscin, a steroidal saponin, and trigonelline, an alkaloid. These phytoestrogens have estrogen-like activities in vitro [6,7]. In addition, fenugreek contains a large quantity of insoluble dietary fibers. These active components might cause several adverse reactions including hypoglycemia, diarrhea and galactorrhea, when an excessive amount of fenugreek was ingested [2,8,9].

The purpose of this study was to examine the dose-dependent effects, safety and tolerability of fenugreek.

* Correspondence: e-muraki@josai.ac.jp
1Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan
Full list of author information is available at the end of the article

© 2011 Muraki et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Methods

Animals and housing

Three-week-old male, Sprague-Dawley rats were obtained from CLEA (Tokyo, Japan). Rats were housed individually in stainless steel wire-bottom cages in a room maintained at 22 ± 2 °C and 55 ± 5% relative humidity with a 12 h cycle of light and dark. Rats were given free access to tap water throughout the experiment. They were fed a commercial diet (CE-2; CLEA) for 1 wk prior to the experiment. The experimental protocol was approved by the Institutional Animal Care and Use Committee of Josai University.

Experimental design

The rats were randomly divided into six groups of 6 rats each. Each group was fed either the high-fat high-sucrose diet (HFS; lard 50% kcal, sucrose 25% kcal) based on the modified version of the AIN-93G [10] as a control (Ctrl group) or the HFS containing 0.25% (VL group), 1.25% (L group), 2.50% (M group), 5.00% (H group) or 12.30% (VH group) fenugreek seeds powder (Gaban Co., Tokyo, Japan) for 12 wks (Table 1). Almost the same energy intake was maintained for all groups by adjusting the dietary intake, and the food consumption in all groups except for the VH group was approximately equivalent to the ad libitum consumption under these conditions. After 12 wks, the rats were individually transferred into the metabolic cage, and urine and feces were separately collected for 1 day. At the end of the experiment, the rats were killed with pentobarbital sodium (100 mg/kg, ip). Blood samples were collected from the abdominal aorta, and the plasma was separated after centrifugation (2,000 × g for 20 min at 4°C) and stored at -30°C until analyzed. After the collection of the blood sample, the liver, interscapular brown adipose tissue (IBAT) and epididymal white adipose tissue (EWAT) were immediately excised, weighed and stored at -30°C for further analyses.

Oral glucose tolerance tests and intraperitoneal insulin tolerance tests

At the 10th wk, the rats were deprived of food for 12 h. Then they were given oral glucose (2 g/kg body weight) for the oral glucose tolerance test (OGTT) and an intraperitoneal injection of human regular insulin (0.75 U/kg body weight) for the intraperitoneal insulin tolerance test (IPITT). Blood glucose concentrations were measured by Ascensia™ DexterZII (Bayer Medical, Tokyo, Japan) using tail blood samples at 0, 30, 60 and 120 min after glucose administration and at 0, 15, 30, 45, 60 and 120 min after insulin administration. Plasma insulin concentrations were measured using a commercial kit (Rat Insulin ELISA kit, Shibayagi Co., Gunma, Japan) using separated tail plasma samples at 0, 30, 60 and 120 min after glucose administration.

Blood analysis

Plasma triglyceride, total cholesterol, AST and ALT were measured by colorimetric slides using the Fuji Dri-Chem 3500 (Fujifilm Corp., Tokyo, Japan).

Hepatic and fecal lipids concentrations

The hepatic and fecal lipids were extracted in accordance with the method of Bligh and Dyer [11] and the method of Folch [12], respectively. Each extract was solubilized by Triton-X100 (Wako Pure Chemical Industries, Osaka, Japan), and the lipids concentrations were determined enzymatically by means of commercial kits (Triglycerides E-Test Wako, Cholesterol E-Test Wako, Total Bile Acid Test Wako; Wako Pure Chemical Industries).

Statistical analysis

All data are expressed as the mean ± SEM. Statistical analyses were carried out using Statistical Package for Social Sciences (SPSS12.0J for Windows; SPSS Japan, Tokyo, Japan). In the three-group comparison, the

Table 1 Experimental diets

| (g) | Ctrl | VL | L | M | H | VH |
|-----|------|----|---|---|---|----|
| Lard | 260.450 | 260.300 | 258.100 | 255.780 | 251.000 | 237.700 |
| Milk casein | 267.100 | 266.380 | 261.900 | 256.700 | 246.380 | 216.500 |
| Sucrose | 316.700 | 316.700 | 314.700 | 312.900 | 309.100 | 298.600 |
| β-Corn starch | 57.698 | 57.170 | 55.136 | 52.343 | 47.019 | 31.577 |
| Vitamin mixture | 10.000 | 10.000 | 10.000 | 10.000 | 10.000 | 9.838 |
| Mineral mixture | 35.000 | 34.923 | 34.613 | 34.225 | 33.450 | 30.621 |
| Cellulose powder | 50.000 | 48.975 | 50.000 | 50.000 | 50.000 | 49.190 |
| L-Cystin | 3.000 | 3.000 | 3.000 | 3.000 | 3.000 | 2.951 |
| t-Butylhydroquinone | 0.052 | 0.052 | 0.052 | 0.052 | 0.051 | 0.050 |
| Fenugreek | - | 2.500 | 12.500 | 25.000 | 50.000 | 122.974 |

Ctrl: Control group, VL: Very low dose of fenugreek group (0.25%), L: Low dose of fenugreek group (1.25%), M: Middle dose of fenugreek group (2.5%), H: High dose of fenugreek group (5.0%), VH: Very high dose of fenugreek group (12.3%). *Based on the AIN-93G and modified. 1Purchased from Oriental Yeast Co., Tokyo, Japan. 2Vitamin mixture was based on the AIN-93 formation, and added with tartaric acid choline. 3Mineral mixture was based on the AIN-93G formation. 4Purchased from Wako Pure Chemical Industries, Osaka, Japan. 5Purchased from Gaban Co., Tokyo, Japan. 6Purchased from Wako Pure Chemical Industries, Osaka, Japan.
effects of treatment were analyzed using one-way analysis of variance (ANOVA), and the differences among means were tested by means of the Tukey's honestly significant difference (HSD) test. In the two-group comparison, the effects of treatment were analyzed through a T-test. In OGTT and IPITT, the effects of treatment were analyzed by means of repeated ANOVA. Differences were considered significant at $P < 0.05$.

**Results**

**Effect of fenugreek on the body weight, energy intake, tissue weights and plasma parameters**

The body weight gain, the EWAT weight and the IBAT weight decreased significantly in the VH group compared to the other groups. No significant difference was found in the liver weight among the groups (Table 2).

No significant difference was found in AST, ALT levels or AST/ALT in the liver among the groups (Table 3).

In OGTT, the blood glucose levels at 120 min in the VH group were significantly lower than those in the Ctrl group (Figure 1A), and the plasma insulin levels at 120 min in the VH group were significantly lower than those in the other groups (Figure 1B). There was no significant difference of the area under the curve (AUC) of glucose among the groups (Figure 1C), but the VH group showed slightly less food intake than the other groups (Figure 1D). Thus fenugreek intake did not show any liver injury.

**Effects of fenugreek on glucose tolerance**

The fasting blood glucose levels decreased significantly in the M and VH groups compared to the Ctrl group, whereas no significant difference was found in the fasting plasma insulin levels or insulin resistance index, HOMAIR (homeostasis model assessment as an index of insulin resistance), among groups (Table 3).

In OGTT, the blood glucose levels at 120 min in the VH group were significantly lower than those in the Ctrl group (Figure 1A), and the plasma insulin levels at 120 min in the VH group were significantly lower than those in other groups (Figure 1B). There was no significant difference of the area under the curve (AUC) of glucose among the groups (Figure 1C), but the VH group showed significant lower AUC of insulin compared to the Ctrl group (Figure 1D).

In IPITT, the blood glucose levels at 60 and 120 min in the VH group were significantly lower than those of the other groups (Figure 2A). AUC of the blood glucose in the VH group was also significantly lower than those of the other groups (Figure 2B).

**Lipids and bile acid levels in plasma, liver and feces**

Although the plasma triglyceride and total cholesterol levels increased slightly in some groups, no dose-dependent effect was found (Table 2). However, the hepatic triglyceride and total cholesterol levels decreased significantly in the M and VH groups compared to the Ctrl group (Figure 3). In feces, the triglyceride levels in the VH group increased remarkably compared to the levels in the other groups. The total cholesterol levels increased significantly in the L group, the H group and the VH group compared to the Ctrl group. Fenugreek elevated the total bile acid levels in feces in a dose-dependent manner (Figure 4).

**Discussion**

Hepatic steatosis is a risk factor for liver cirrhosis and atherosclerosis. Both the liver and adipocytes play a major role in the regulation of cellular and circulating serum lipids, predominantly triglyceride and cholesterol. In our previous studies, fenugreek decreased the hepatic triglyceride and total cholesterol levels in normal rats fed with a high-fat high-sucrose diet [13,14]. The present study investigated dose-dependent effects of fenugreek and its safety and tolerability.

The body weight gain and EWAT and IBAT weights in the VH group decreased significantly as compared with all of the other groups. In a pair feeding procedure, the VH group showed slightly less food intake than the other groups. It has been reported that the reduced food intake in the presence of soluble fibers such as galactomannan

**Table 2 Effect of fenugreek on the body weight, energy intake, tissue weights and plasma**

| (g) | Ctrl | VL | L | M | H | VH |
|-----|------|----|---|---|---|----|
| Body weight gain (g) | 500.6 ± 18.5a | 491.2 ± 10.2a | 486.7 ± 18.5a | 463.9 ± 10.2a | 480.6 ± 18.5a | 408.4 ± 10.2b |
| EER1 (mg/kJ) | 15.6 ± 0.3a | 15.3 ± 0.1a | 15.6 ± 0.3a | 14.6 ± 0.2ab | 15.4 ± 0.3a | 13.4 ± 0.5b |
| Liver weight (g) | 193.1 ± 11.3 | 200.0 ± 6.0 | 183.0 ± 0.7 | 172.6 ± 0.6 | 180.0 ± 0.8 | 173.0 ± 1.0 |
| EWAT2 weight (g) | 15.3 ± 0.5a | 15.9 ± 0.9a | 13.6 ± 0.7ab | 14.5 ± 0.7a | 163.0 ± 1.4a | 101.0 ± 1.0b |
| IBAT3 weight (g) | 0.77 ± 0.04 | 0.76 ± 0.04 | 0.74 ± 0.05 | 0.83 ± 0.05 | 0.78 ± 0.08 | 0.55 ± 0.03* |
| Plasma TG4 (mmol/L) | 1.64 ± 0.51 | 1.98 ± 0.61 | 2.06 ± 0.29 | 1.79 ± 0.29 | 3.63 ± 0.73 | 2.47 ± 0.46* |
| Plasma TC5 (mmol/L) | 1.50 ± 0.14 | 1.94 ± 0.14 | 1.73 ± 0.17 | 1.83 ± 0.17* | 1.72 ± 0.13 | 1.70 ± 0.12 |
| AST (U/L) | 66.2 ± 8.0 | 76.2 ± 10.6 | 94.3 ± 21.7 | 98.5 ± 25.7 | 67.7 ± 9.1 | 74.8 ± 8.2 |
| ALT (U/L) | 173.0 ± 7.0 | 212.0 ± 32.0 | 225.0 ± 39.0 | 250.0 ± 46.0 | 192.0 ± 24.0 | 222.0 ± 14.0 |
| AST/ALT6 | 1.08 ± 0.11 | 1.03 ± 0.04 | 1.14 ± 0.06 | 1.05 ± 0.08 | 1.02 ± 0.09 | 0.95 ± 0.07 |

Ctrl: Control group; VL: Very low dose of fenugreek group (0.25%); L: Low dose of fenugreek group (1.25%); M: Middle dose of fenugreek group (2.5%); H: High dose of fenugreek group (5.0%); VH: Very high dose of fenugreek group (12.3%). EER (mg/kJ) = Body weight gain (mg)/Total food intake (kJ). EWAT: Epididymal white adipose tissue. IBAT: Interscapular brown adipose tissue. TG: Triglyceride. TC: Total cholesterol. The relative values for Normal rats’ data; AST/ALT = AST (U/L)/ALT (U/L)/Normal rats’ data. Values are expressed as means ± SEM for 6 rats. Means without a common superscript letter are significantly different, $P < 0.05$ (ANOVA). Asterisks indicate a difference from Ctrl $P < 0.05$ (t-test).
Table 3 Insulin resistance index

|                  | Ctrl   | VL    | L      | M      | H      | VH     |
|------------------|--------|-------|--------|--------|--------|--------|
| Fasting blood glucose (mmol/L) | 6.27 ± 0.24<sup>a</sup> | 6.19 ± 0.22<sup>b</sup> | 5.50 ± 0.28<sup>d</sup> | 5.20 ± 0.15<sup>c</sup> | 5.60 ± 0.34<sup>d</sup> | 5.03 ± 0.11<sup>c</sup> |
| Fasting blood insulin (pmol/L)  | 129 ± 37 | 167 ± 35 | 56 ± 27 | 117 ± 29 | 94 ± 33 | 54 ± 10 |
| HOMA-IR<sup>1</sup>         | 1.00 ± 0.28 | 1.69 ± 0.49 | 0.85 ± 0.52 | 0.78 ± 0.20 | 0.98 ± 0.36 | 0.35 ± 0.06 |

Ctrl: Control group, VL: Very low dose of fenugreek group (0.25%), L: Low dose of fenugreek group (1.25%), M: Middle dose of fenugreek group (2.5%), H: High dose of fenugreek group (5.0%), VH: Very high dose of fenugreek group (12.3%).<sup>1</sup> Relative values of (fasting blood glucose × fasting blood insulin) compared to the mean value of the Ctrl group. Values are expressed as means ± SEM for 6 rats. Means without a common superscript letter are significantly different, <i>P</i> < 0.05 (ANOVA).

Muraki et al. Lipids in Health and Disease 2011, 10:240
http://www.lipidworld.com/content/10/1/240

Page 4 of 6
moted, and the inflammation in adipose tissue is inhibited and the size reduction. As a result, the secretion of mono-
gliver [22-24]. In addition, diosgenin enhances the peroxi-
and the increase of glycogen synthesis in the muscle and
metabolism with up-regulation of several enzymes [19-23]
This effect is brought by the activation of glucose and lipid
insulin sensitivity through the activation of insulin signal-
group. It has been reported that fenugreek also enhances
fenugreek inhibited insulin secretion only in the VH
low min in the VH group. Further, fenugreek inhibited insulin secretion only in the VH
has been reported that fenugreek also enhances insulin sensitivity through the activation of insulin signal-
ing at an early stage in peripheral tissues and liver [19].
This effect is brought by the activation of glucose and lipid metabolism with up-regulation of several enzymes [19-23] and the increase of glycogen synthesis in the muscle and liver [22-24]. In addition, diosgenin enhances the peroxisome proliferator-activated receptor-\(\gamma\) (PPAR\(\gamma\)) level in EWAT and promotes both the adipocyte differentiation and the size reduction. As a result, the secretion of monocyte chemoattractant protein-1 (MCP-1) in adipocytes is suppressed, while the secretion of adiponectin is promoted, and the inflammation in adipose tissue is inhibited 

![Figure 3 Effect of fenugreek on the hepatic triglyceride [A] and total cholesterol [B] levels. Ctrl: Control group, VL: Very low dose of fenugreek group (0.25%), L: Low dose of fenugreek group (1.25%), M: Middle dose of fenugreek group (2.5%), H: High dose of fenugreek group (5.0%), VH: Very high dose of fenugreek group (12.3%). Values are expressed as means \(\pm\) SEM for 6 rats. Means without a common superscript letter are significantly different, \(P < 0.05\) (ANOVA).](image1)

![Figure 4 Effect of fenugreek on the fecal triglyceride [A], total cholesterol [B] and total bile acid secretion [C] levels. Ctrl: Control group, VL: Very low dose of fenugreek group (0.25%), L: Low dose of fenugreek group (1.25%), M: Middle dose of fenugreek group (2.5%), H: High dose of fenugreek group (5.0%), VH: Very high dose of fenugreek group (12.3%). Means without a common superscript letter are significantly different, \(P < 0.05\) (ANOVA).](image2)

[18,25]. Therefore, we assume that fenugreek activated firstly insulin sensitivity rather than insulin secretion in the relatively mild metabolic disorders we generated in rats through high-fat high-sucrose diets. The VH group showed appetite reduction and diarrhea, while no rats in the M group showed any adverse effects or symptoms.

These results suggest that fenugreek dose-dependently inhibited lipid accumulation in the liver by increasing the lipid and bile acids excretion in the feces, and that an effective, safe and tolerable dose of fenugreek was around 2.50% (w/w).

**Acknowledgements**

This study was supported by Urakami Foundation (Tokyo, Japan) and House Foods Corporation (Tokyo, Japan).

**Author details**

1. Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama 350-0295, Japan. 2. Koken Medicare, Saitama 336-0018, Japan.

**Authors’ contributions**

EM conceived the study and its design, wrote the manuscript, and carried out the experiments. VH carried out experiments and analyzed data. HC and NT participated in study design and helped to draft the manuscript. KK conceived the study, participated in its design and helped to draft the manuscript. All authors read and approved the final manuscript.

**Authors’ information**

Department of Clinical Dietetics & Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Saitama, Japan.

**Competing interests**

The authors declare that they have no competing interests.

**Received: 24 November 2011 Accepted: 21 December 2011 Published: 21 December 2011**

**References**

1. Watanabe S, Zhuo XG, Kimira M: Food safety and epidemiology: new database of functional food factors. BioFactors 2004, 22:213-9.
2. Broc A, Gross R, Petit P, Sauvaire Y, Manteghetti M, Tourier M, Masiello P, Gomis R, Ribas G: 4-Hydroxyisoleucine: experimental evidence of its insulinotropic and anti-diabetic properties. Am J Physiol 1999, 277:E617-23.
3. Jette L, Harvey L, Eugeni K, Levens N: 4-Hydroxyisoleucine: a plant-derived treatment for metabolic syndrome. Curr Opin Investig Drugs 2009, 10:353-8.
4. Srichamroen A, Thomson AB, Field CJ, Basu TK: In vitro intestinal glucose uptake is inhibited by galactomannan from Canadian fenugreek seed (Trigonella foenum graecum L.) in genetically lean and obese rats. Nutr Res 2009, 29:49-54.
5. Srichamroen A, Field CJ, Thomson AB, Basu TK: The modifying effects of galactomannan from Canadian-grown fenugreek (Trigonella foenum-graecum L.) on the glycemic and lipidemic status in rats. J Clin Biochem Nutr 2008, 43:167-74.
6. Sreeja S, Anju VS, Sreeja S: In vitro estrogenic activities of fenugreek Trigonella foenum graecum seeds. Indian J Med Res 2010, 131:814-9.
7. Sebastian KS, Thampan RV: Differential effects of soybean and fenugreek extracts on the growth of MCF-7 cells. Chem Biol Interact 2007, 170:135-43.
8. Lewis JH: Esophageal and small bowel obstruction from guar gum containing "diet pills": analysis of 26 cases reported to the Food and Drug Administration. Am J Gastroenterol 1992, 87:1424-8.
9. Zuppa AA, Sindico P, Orchi C, Carducci C, Cardiello V, Romagnoli C: Safety and efficacy of galactogogues: substances that induce, maintain and increase breast milk production. J Pharm Pharm Sci 2010, 13:162-74.
10. Reeves PG, Nielsen FH, Fahey GC Jr: AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993, 123:1939-51.
11. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-7.
12. Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
13. Muraki E, Matsuoka C, Oikawa R, Sato S, Chiba H, Tsunoda N, Kasono K: Fenugreek attenuates lipid accumulation in normal rats. J Jpn Nutr Food Sci 2011, 64:99-106, (in Japanese).
14. Muraki E, Chiba H, Tsunoda N, Kasono K: Fenugreek improves diet-induced metabolic disorders in rats. Horm Metab Res.
15. Ramadan G, El-Beih NM, Abd El-Kareem HF: Anti-metabolic syndrome and immunostimulant activities of Egyptian fenugreek seeds in diabetic obese and immunosuppressive rat models. Br J Nutr 2010, 105:995-1004.
16. Reddy RR, Srinivasan K: Effect of dietary fenugreek seeds on biliary proteins which influence nucelation of cholesterol crystals in bile. Steroids 2011, 76:455-63.
17. Uemura T, Goto T, Kang MS, Mizoguchi N, Hirai S, Lee JY, Nakan Y, Shono J, Hoshino S, Takei M, Tsuge N, Narukami T, Makishima M, Takahashi N, Kawada T: Diosgenin, the major aglycon of fenugreek, inhibits LXRs activity in HepG2 cells and decreases plasma and hepatic triglycerides in obese diabetic mice. J Nutr 2011, 141:17-23.
18. Sauvaire Y, Petit P, Broca C, Manteghetti M, Baisas Y, Fernandez-Alvarez J, Gross R, Roye M, Leconte A, Gomis R, Ribes G: 4-Hydroxysisoleucine: a novel amino acid potentiator of insulin secretion. Diabetes 1998, 47:206-10.
19. Mohammad S, Taha A, Akhtar K, Bamezai RN, Baquer NZ: In vivo effect of Trigonella foenum graecum on the expression of pyruvate kinase, phosphoenolpyruvate carboxykinase, and distribution of glucose transporter (GLUT4) in alloxan-diabetic rats. Can J Physiol Pharmacol 2006, 84:647-54.
20. Raju J, Gupta D, Rao AR, Yadava PK, Baquer NZ: Trigonellafoenum graecum (fenugreek) seed powder improves glucose homeostasis in alloxan diabetic rat tissues by reversing the altered glycolytic, gluconeogenic and lipogenic enzymes. Mol Cell Biochem 2001, 224:45-51.
21. Mohamad S, Taha A, Bamezai RN, Basir SF, Baquer NZ: Lower doses of vanadate in combination with trigonella restore altered carbohydrate metabolism and antioxidant status in alloxan-diabetic rats. Clin Chim Acta 2004, 342:105-14.
22. Gad MZ, El-Sawalhi AM, Ismail MF, El-Tanbouly ND: Biochemical study of the anti-diabetic action of the Egyptian plants Fenugreek and Balanites. Mol Cell Biochem 2006, 281:173-83.
23. Vats V, Yadav SP, Grover JR: Effect of T. foenumgraecum on glycogen content of tissues and the key enzymes of carbohydrate metabolism. J Ethnopharmacol 2003, 85:237-42.
24. Ruby BC, Gaskill SE, Slivka D, Harger SG: The addition of fenugreek extract (Trigonella foenum-graecum) to glucose feeding increases muscle glycogen resynthesis after exercise. Amino Acids 2005, 28:71-6.
25. Hirai S, Uemura T, Mizoguchi N, Lee JY, Takei M, Nakano Y, Hoshino S, Tsuge N, Narukami T, Yu R, Takahashi N, Kawada T: Diosgenin attenuates inflammatory changes in the interaction between adipocytes and macrophages. Mol Nutr Food Res 2010, 54:797-804.

doi:10.1186/1476-511X-10-240
Cite this article as: Muraki et al.: Dose-dependent effects, safety and tolerability of fenugreek in diet-induced metabolic disorders in rats. Lipids in Health and Disease 2011 10:240.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit